ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

• Revenue in USD (TTM)0.00
• Net income in USD-110.78m
• Incorporated2014
• Employees107.00

• Location
  Oric Pharmaceuticals Inc240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
• Phone+1 (650) 388-5600
• Fax+1 (302) 655-5049
• Websitehttp://oricpharma.com/